The Journal of Experimental Medicine
Randox
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 16 April 2001.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Friedman, J. S.
Right arrow Articles by Burakoff, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedman, J. S.
Right arrow Articles by Burakoff, S. J.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Antioxidants
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2001/4/925/ $5.00
The Journal of Experimental Medicine, Volume 193, Number 8, April 16, 2001 925-934

Original Article

Absence of Mitochondrial Superoxide Dismutase Results in a Murine Hemolytic Anemia Responsive to Therapy with a Catalytic Antioxidant

Jeff S. Friedmana, Vivienne I. Rebelb, Ryan Derbya, Kirsten Bella, Ting-Ting Huangc, Frans A. Kuypersd, Charles J. Epsteinc, and Steven J. Burakoffa
a Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115
b Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts 02115
c Department of Pediatrics, University of California San Francisco, San Francisco, California 94143
d Children's Hospital Oakland Research Institute, Oakland, California 94609

Correspondence to: Jeff S. Friedman, Dept. of Pediatric Oncology, Dana Farber Cancer Institute, Rm. M654, Boston, MA 02115. Tel:617-632-5123 Fax:617-632-5144 E-mail:jeff_friedman{at}dfci.harvard.edu.

Manganese superoxide dismutase 2 (SOD2) is a critical component of the mitochondrial pathway for detoxification of O2-, and targeted disruption of this locus leads to embryonic or neonatal lethality in mice. To follow the effects of SOD2 deficiency in cells over a longer time course, we created hematopoietic chimeras in which all blood cells are derived from fetal liver stem cells of Sod2 knockout, heterozygous, or wild-type littermates. Stem cells of each genotype efficiently rescued hematopoiesis and allowed long-term survival of lethally irradiated host animals. Peripheral blood analysis of leukocyte populations revealed no differences in reconstitution kinetics of T cells, B cells, or myeloid cells when comparing Sod2+/+, Sod2-/-, and Sod2+/- fetal liver recipients. However, animals receiving Sod2-/- cells were persistently anemic, with findings suggestive of a hemolytic process. Loss of SOD2 in erythroid progenitor cells results in enhanced protein oxidative damage, altered membrane deformation, and reduced survival of red cells. Treatment of anemic animals with Euk-8, a catalytic antioxidant with both SOD and catalase activities, significantly corrected this oxidative stress–induced condition. Such therapy may prove useful in treatment of human disorders such as sideroblastic anemia, which SOD2 deficiency most closely resembles.

Key Words: transplantation (fetal liver), oxidative stress, antioxidant, stem cells, SOD2


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS